SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861) 1, ...

Today will be largely cloudy with scattered, blustery showers moving in from the west, these heavy at times with a risk of thunder. A few brief brighter spells at times. Tonight This evening and the ...

We’re having problems displaying this forecast. Please try again later. This video can not be played Today Today will be windy with sunny spells and variable cloud in the morning. Cloudier with ...

Takeda has said it intends to move quickly ahead with regulatory filings for oveporexton, its orexin agonist for sleep disorder narcolepsy, after a clean sweep of positive efficacy data in two phase 3 ...